Characterization of Oral and Gut Microbiota in Patients with Psoriatic Diseases: A Systematic Review

Gut dysbiosis in rheumatic diseases: A systematic review and meta-analysis of 92 observational studies

“… 34 Several systematic reviews on gut dysbiosis in specific rheumatic diseases have been published. 41 , 42 , 43 , 44 Of these, Chu et al. analysed 26 case-control studies and found that either decreased or unchanged α-diversity was commonly seen in patients with rheumatoid arthritis, and the depletion of genus Faecalibacterium was also reported frequently in such patients.…”

“… 43 The review by Wang et al., including 14 case-control studies, reported a remarkably increased α-diversity in patients with ankylosing spondylitis, accompanied by increased amounts of genus Dialister and Streptococcus as well as decreased amounts of genus Parasutterella . 44 The remaining two reviews concluded that the gut microbiota in patients with psoriatic arthritis 42 and fibromyalgia 41 was different from that in controls, but the findings were heterogeneous. In our study, we included 92 observational studies spanning 14 rheumatic diseases and revealed that gut microbiota dysbiosis was associated with rheumatic diseases in general with predominantly non-specific, shared alterations of microbes.…”

Successful treatment of psoriasis with adalimumab induced no changes in the gut microbiota

“…Editor, Atopic dermatitis (AD) carries a substantial disease burden and has a profound impact on quality of life. 1,2 Despite extensive research investigating burden of disease in AD, there is a paucity of research on burden of treatment (BOT) in AD. BOT is the workload of healthcare for patients with chronic conditions and the effects of this on well-being.…”

“…To the Editor, Patients with psoriasis display a distinct gut microbiota compared with healthy. 1 However, studies examining the potential modulatory treatment effects for psoriasis on the gut microbiota in patients with psoriasis are scarce. We conducted a pilot-study to investigate the effect of the TNF-a-inhibitor, adalimumab, on the gut microbiota in patients with psoriasis.…”

Ceramides in Autoimmune Rheumatic Diseases: Existing Evidence and Therapeutic Considerations for Diet as an Anticeramide Treatment

“…Furthermore, the large majority of patients with AIRDs also demonstrate overweight and obesity, aggravated by physical inactivity [ 18 , 19 ]. In parallel, cachexia [ 20 ], micronutrient deficiencies [ 21 , 22 , 23 , 24 , 25 ], gut dysbiosis [ 26 , 27 , 28 , 29 ], poor diet quality [ 30 , 31 , 32 ] and malnutrition [ 33 ] are frequent nutritional issues among patients with rheumatic conditions; thus, the need for a comprehensive dietary approach and treatment is a necessity.…”